THE DEVPRO BIOPHARMA TEAM IS STEEPED IN TECHNICAL KNOW-HOW. THE EXECUTIVE TEAM REPRESENTS OVER 100 YEARS CUMULATIVE CLINICAL DEVELOPMENT EXPERIENCE.
The DevPro Biopharma team is known throughout the industry for reimagining clinical trial development and execution with the result of improving quality, de-risking, accelerating timelines, and saving money.
VISIONARY LEADERS
COLIN REISNER
Co-Founder and CEO
Colin is a physician and innovative leader with more than 25 years of international experience at large pharmaceutical companies and start-up biotech, including: AstraZeneca, Pearl Therapeutics, GlaxoSmithKline, Novartis, and Boehringer Ingelheim. Prior to DevPro Biopharma Colin held a dual role of CEO, Pearl Therapeutics, and SVP, Head of Late Respiratory, Inflammation and Autoimmunity at AstraZeneca. Colin has been involved in development of over 20 life changing medications.
Colin is a well-respected thought-leader who often presents at international congresses, and has published over 50 papers in high quality journals including: NEJM, JAMA, Lancet Respiratory, and Chest.
A Diplomate of the American Board of Allergy and Immunology, Fellow of the American College of Chest Physicians, American Academy of Allergy Asthma & Immunology, and active member of the American Thoracic Society, Colin has a passion for improving the lives of patients.
EARL ST. ROSE
Co-Founder and COO
Earl brings over 30 years of large pharmaceutical companies and start-up biotech experience across development and clinical research in several therapeutic areas, including respiratory, oncology, endocrinology, and pain management. Prior to DevPro Biopharma, Earl held a dual role of VP, Pearl Therapeutics Clinical Development & Operations, and VP, Head of Innovation, AstraZeneca.
With a BS in Microbiology, MS in Microbiology and Molecular Genetics, and an MBA in Global Management, Earl is a passionate and creative leader with a proven track record for developing successful teams, building global organizations, and transforming company capabilities.
EXECUTIVE TEAM
PRAMILA MONTE
VP, Head of Clinical Safety Management, Portfolio Manager
Pramila is a strategic and progressive leader with over 15 years experience overseeing pharmacovigilance, clinical safety management, and global health authority inspections.
She is a key leader in transforming organizational efficiency by introducing new innovations, standardization, and process improvements.
CATHERINE PELC
VP, Head of Business Process & Operations, Portfolio Manager
_
Cathy is a clinical operations leader with over 20 years of experience in companies ranging from start-ups to large pharma, with experience in respiratory, neonatology, cardiovascular, hematology, oncology, and medical devices.
Her expertise ranges from implementing and simplifying internal processes and procedures to leading transformative company change management initiatives.
KIM ROSSMAN
VP, Head of Clinical Execution, Portfolio Manager
_
Kim is a clinical trial execution leader with over 23 years of experience developing products in anesthesia, CNS, opthalmology, and respiratory portfolios.
With extensive experience supporting global site inspections and sponsor health authority inspections, including FDA, EMA, PMDA (Japan) and CFDI (China), Kim is uniquely qualified to lead clinical development programs by consistently ensuring that quality systems operate to the highest standards.
